Inclusion Criteria:

- Patients with histologic confirmation of a solid tumor malignancy with clinical
evidence of metastatic disease.

- Patients must have failed at least one standard therapy, if available, for their
malignancy. Patients may be entered on the trial without prior therapy if there is
no standard effective therapy available.

- No active brain metastases or epidural tumor.

Exclusion Criteria:

- Concomitant administration of steroids.

- Irradiation or chemotherapy within 14 days of start of protocol.

- Evidence of another active cancer, except for non-melanoma, carcinoma of the skin and
in-situ carcinoma of the cervix curatively treated, Stage I or II cancer from which
the patient is currently in complete remission, or any other cancer from which the
patient has been disease free for greater than 5 years.

- Women who are pregnant or lactating. Women or men of reproductive age who are
unwilling to use two forms of effective contraception.

- Patients with clinically significant cardiac, renal or hepatic disease; severe
debilitating pulmonary disease; or history of diabetes mellitus prone to
ketoacidosis.

- Patients with a history of pancreatitis.

- Patients with known hypersensitivity to retinoids or retinoic acid derivatives.

- Patients with coagulation disorders, such as thrombophlebitis or pulmonary embolism.

- Patients with pre-existing psychiatric condition, especially depression or a history
of severe uncontrolled psychiatric disorder.

- Patients with pre-existing thyroid abnormalities whose thyroid function cannot be
maintained in the normal range.

- Patients with chronic moderate to severe nausea.

- Patients with history of epilepsy or a seizure disorder taking anti-convulsant
medication.